YKL-40, cardiovascular events, and mortality in individuals recently diagnosed with type 2 diabetes: A Danish cohort study
Authors' conclusion
YKL-40 is a prognostic biomarker for most CVEs, and even more so for all-cause mortality, primarily driven by cancer-related causes.
Study context
- Population
- Danish individuals recently diagnosed with T2D, followed up to 14 yearsYKL-40 measured in 9,010
- Participants
- 11,346 participants
- Exposure
- YKL-40 percentile categories
- Outcome
- Cardiovascular events (CVEs) (AF, ischemic stroke, venous thromboembolism (VTE), MI, heart failure (HF), peripheral artery disease (PAD)) and all-cause, cardiovascular and cancer mortality
- Follow-up
- Up to 14 years
Main finding
As reported in the abstract
Each group vs 0-33%Estimate (95% CI)
91-100%
adjusted HR, AF 1.31(1.04–1.66)
91-100%
adjusted HR, ischemic stroke 1.43(0.98–2.07)
91-100%
adjusted HR, VTE 1.07(0.65–1.76)
91-100%
adjusted HR, MI 0.88(0.52–1.48)
91-100%
adjusted HR, HF 1.66(1.19–2.31)
91-100%
adjusted HR, PAD 1.66(1.12–2.48)
91-100%
adjusted HR, all-cause mortality 2.18(1.85–2.56)
91-100%
adjusted HR, cardiovascular mortality 1.64(1.07–2.50)
91-100%
adjusted HR, cancer mortality 2.73(2.05–3.63)
Observational data: associations, not effects.
Further findings
Per 1 SD log increase in YKL-40 vs CRP (CRP measured in 9,644)
- Each 1 SD log increase in YKL-40 and CRP similarly increased CVE risks; CRP superior for myocardial infarction (MI) and cardiovascular mortality
Original publication
YKL-40, cardiovascular events, and mortality in individuals recently diagnosed with type 2 diabetes: A Danish cohort study. Diabetes Res Clin Pract. Published 22 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →